Q-omics provides the consensus-scored TKTL2 profile across patient tissues and cancer cell-line models. TKTL2 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TKTL2 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, TKTL2 RNA expression shows 9,292 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, KIRC, and TGCT as cancer lineages where TKTL2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TKTL2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TKTL2 survival associations across molecular data types. TKTL2 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TKTL2 RNA expression–survival associations across cancer types. High TKTL2 expression shows unfavorable associations in LUSC, PRAD, LAML and LUAD, but favorable associations in HNSC and SKCM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .005). Together, the overview and detailed table identify HNSC as the clearest survival context for TKTL2 RNA expression.
This table summarizes TKTL2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TKTL2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TKTL2 shows lower tumor expression in KIRC, BRCA and KICH and higher tumor expression in STAD, LUAD and CHOL. The KIRC box plot shows higher TKTL2 RNA expression in normal versus tumor tissue (log2 FC = −0.045, t-test p < 0.001).
This table shows molecular features associated with TKTL2 in patient tissues and cancer cell lines. In patient samples, TKTL2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TKTL2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in CNS and LARGE_INTESTINE.
